ES2183289T3 - Antagonistas de 5-ht1a y 5-ht1d alfa. - Google Patents

Antagonistas de 5-ht1a y 5-ht1d alfa.

Info

Publication number
ES2183289T3
ES2183289T3 ES98304162T ES98304162T ES2183289T3 ES 2183289 T3 ES2183289 T3 ES 2183289T3 ES 98304162 T ES98304162 T ES 98304162T ES 98304162 T ES98304162 T ES 98304162T ES 2183289 T3 ES2183289 T3 ES 2183289T3
Authority
ES
Spain
Prior art keywords
ht1a
alfa
ht1d
antagonists
ht1d antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98304162T
Other languages
English (en)
Inventor
Vincent Patrick Rocco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2183289T3 publication Critical patent/ES2183289T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA NUEVA CLASE DE DERIVADOS SUSTITUIDOS ARILOXI - 2 - OL - 3 - (4 - ESPIRO (ALCANODIOXI)ISOBENZOFURANIL - Y FTALOIL - PIPERIDINA), UTILES COMO ANTAGONISTAS DE 5 - HT 1A Y 5 - HT 1D AL .
ES98304162T 1997-05-29 1998-05-27 Antagonistas de 5-ht1a y 5-ht1d alfa. Expired - Lifetime ES2183289T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4825697P 1997-05-29 1997-05-29

Publications (1)

Publication Number Publication Date
ES2183289T3 true ES2183289T3 (es) 2003-03-16

Family

ID=21953552

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98304162T Expired - Lifetime ES2183289T3 (es) 1997-05-29 1998-05-27 Antagonistas de 5-ht1a y 5-ht1d alfa.

Country Status (8)

Country Link
EP (1) EP0881224B1 (es)
JP (1) JP2002500668A (es)
AT (1) ATE223416T1 (es)
AU (1) AU7378698A (es)
CA (1) CA2291674A1 (es)
DE (1) DE69807578T2 (es)
ES (1) ES2183289T3 (es)
WO (1) WO1998053823A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301066A (en) * 2020-09-04 2023-05-01 Gilgamesh Pharmaceuticals Inc Azetidinyl tryptamines and methods for the treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031224A (en) * 1976-04-29 1977-06-21 American Hoechst Corporation 1,3-Dihydro-heteroarylspiro (isobenzofuran)s
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
FR2689509B1 (fr) * 1992-04-01 1994-06-03 Adir Nouveaux derives spiraniques du 3-amino chromane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
DE69807578D1 (de) 2002-10-10
ATE223416T1 (de) 2002-09-15
DE69807578T2 (de) 2003-05-22
EP0881224A1 (en) 1998-12-02
JP2002500668A (ja) 2002-01-08
CA2291674A1 (en) 1998-12-03
AU7378698A (en) 1998-12-30
EP0881224B1 (en) 2002-09-04
WO1998053823A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
CO4230019A1 (es) Antagonistas de neuroquinina diazabiciclica
DE50000102D1 (de) Pyrogen hergestelltes Aluminiumoxid
DE59510421D1 (de) Substituierte Pyridylpyrazole
ATE238790T1 (de) Verwendung von pramipexole als neuroschutzmittel
AR038427A2 (es) Compuestos 15-alquil-14-hidroxilo de marcfortina y parahercuamida
ID21924A (id) Olanzapin dihidrat d
DE59901988D1 (de) Verwendung von Betainen als Antitranspirantien
ATE206877T1 (de) Fluorierte kasein-mizellen
NO971248L (no) 5<alfa>-reduktaseinhibitorer
ITMI921569A1 (it) N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica, dopaminergica e adrenergica
ATE259825T1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
ATE371672T1 (de) Kollagenähnliche verbindungen
NO993647D0 (no) Endotelinantagonist
DK0406211T3 (da) Fucosidase-inhibitorer
ES2183289T3 (es) Antagonistas de 5-ht1a y 5-ht1d alfa.
FI930092A0 (fi) Indanopyrrolidinkarbamater
DK0532629T3 (da) 1-Piperidinyl-alkanoylarylsulfonamid-derivater
ATE137225T1 (de) Dihydrochinolin nmda antagonisten
ATE131172T1 (de) Heterocyclische nmda antagonisten.
NO863647L (no) Propanolderivater.
ES2178335T3 (es) Utilizacion de sulfobetalinas como agentes antitranspirantes.
GT199900060A (es) Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
FR2758819B1 (fr) Indometacine calcique et sa preparation
KR940022669U (ko) 상표의 표시가 지워지지 않는 비누